ATE487476T1 - Neue ppar-liganden, die keine flüssigkeitsretentionen, ödeme oder kongestive herzinsuffizienzen verursachen - Google Patents

Neue ppar-liganden, die keine flüssigkeitsretentionen, ödeme oder kongestive herzinsuffizienzen verursachen

Info

Publication number
ATE487476T1
ATE487476T1 AT07010221T AT07010221T ATE487476T1 AT E487476 T1 ATE487476 T1 AT E487476T1 AT 07010221 T AT07010221 T AT 07010221T AT 07010221 T AT07010221 T AT 07010221T AT E487476 T1 ATE487476 T1 AT E487476T1
Authority
AT
Austria
Prior art keywords
angiotensin
edema
type
heart failure
congestive heart
Prior art date
Application number
AT07010221T
Other languages
English (en)
Inventor
Harrihar A Pershadsingh
Original Assignee
Bethesda Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31721501&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE487476(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bethesda Pharmaceuticals Inc filed Critical Bethesda Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE487476T1 publication Critical patent/ATE487476T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Lubricants (AREA)
AT07010221T 2002-08-10 2003-08-08 Neue ppar-liganden, die keine flüssigkeitsretentionen, ödeme oder kongestive herzinsuffizienzen verursachen ATE487476T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40242502P 2002-08-10 2002-08-10
US45521103P 2003-03-15 2003-03-15
US10/627,372 US7232828B2 (en) 2002-08-10 2003-07-24 PPAR Ligands that do not cause fluid retention, edema or congestive heart failure

Publications (1)

Publication Number Publication Date
ATE487476T1 true ATE487476T1 (de) 2010-11-15

Family

ID=31721501

Family Applications (3)

Application Number Title Priority Date Filing Date
AT03785060T ATE363277T1 (de) 2002-08-10 2003-08-08 Neue ppar-liganden, die keine flüssigkeitsretention, ödem oder dekompensierte herzinsuffizienz verursachen
AT07010221T ATE487476T1 (de) 2002-08-10 2003-08-08 Neue ppar-liganden, die keine flüssigkeitsretentionen, ödeme oder kongestive herzinsuffizienzen verursachen
AT07015887T ATE536183T1 (de) 2002-08-10 2003-08-08 Telmisartan zur behandlung der polyzystischen nierenerkrankung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT03785060T ATE363277T1 (de) 2002-08-10 2003-08-08 Neue ppar-liganden, die keine flüssigkeitsretention, ödem oder dekompensierte herzinsuffizienz verursachen

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT07015887T ATE536183T1 (de) 2002-08-10 2003-08-08 Telmisartan zur behandlung der polyzystischen nierenerkrankung

Country Status (14)

Country Link
US (8) US7232828B2 (de)
EP (6) EP1886683B1 (de)
JP (3) JP4669285B2 (de)
KR (4) KR100830861B1 (de)
CN (6) CN100548293C (de)
AT (3) ATE363277T1 (de)
AU (2) AU2003259081B2 (de)
CA (1) CA2494909C (de)
DE (2) DE60314155T2 (de)
DK (2) DK1536785T3 (de)
ES (2) ES2385936T3 (de)
MX (1) MXPA05001543A (de)
PL (1) PL375189A1 (de)
WO (1) WO2004014308A2 (de)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7232828B2 (en) * 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10335027A1 (de) * 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
EP1818056A1 (de) * 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
DE10301371A1 (de) * 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
US20050020654A1 (en) * 2003-03-15 2005-01-27 Pershadsingh Harrihar A. Novel PPAR agonists, pharmaceutical compositions and uses thereof
SE0300988D0 (sv) * 2003-04-03 2003-04-03 Astrazeneca Ab New use
DE10319592A1 (de) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
US20040223962A1 (en) * 2003-05-07 2004-11-11 Riordan Neil H. Method and composition for preventing or reducing edema, deep vein thrombosis and/or pulmonary embolism
US20050149174A1 (en) * 2003-12-18 2005-07-07 Medtronic Vascular, Inc. Medical devices to treat or inhibit restenosis
DE102004010207A1 (de) * 2004-03-02 2005-09-15 Aventis Pharma S.A. Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate
DE102004010194A1 (de) * 2004-03-02 2005-10-13 Aventis Pharma Deutschland Gmbh 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate, ihre Herstellung und Verwendung in Arzneimitteln
EP1799203A1 (de) * 2004-10-07 2007-06-27 Takeda Pharmaceutical Company Limited Mittel zur prophylaxe oder behandlung des metabolischen syndroms
PL1814527T5 (pl) * 2004-11-05 2021-08-02 Boehringer Ingelheim International Gmbh Dwuwarstwowa tabletka zawierająca telmisartan i amlodypinę
EP1853258A4 (de) * 2005-03-03 2008-05-07 Smithkline Beecham Corp Medikamente
US8288438B2 (en) 2005-03-21 2012-10-16 Metabolex, Inc. Methods for avoiding edema in the treatment or prevention of PPARγ-responsive diseases, including cancer
RU2420280C2 (ru) * 2005-04-21 2011-06-10 Сантен Фармасьютикал Ко., Лтд Терапевтическое средство против кератоконъюнктивального расстройства
EP1904652A2 (de) 2005-07-08 2008-04-02 Brystol-Myers Squibb Company Mit dosisabhängigem ödem assoziierte einzelnukleotid-polymorphismen und verfahren zur verwendung davon
KR101452518B1 (ko) * 2005-08-22 2014-10-21 멜리어 파마슈티칼스 아이, 인코포레이티드 Ｌｙｎ 키나제 활성의 조절 및 관련된 장애의 치료를 위한방법 및 제제
ATE526318T1 (de) 2005-12-19 2011-10-15 Glaxosmithkline Llc Farnesoid-x-rezeptor-agonisten
US20080004281A1 (en) * 2006-06-28 2008-01-03 Kalypsys, Inc. Methods for the modulation of crp by the selective modulation of ppar delta
FR2903984B1 (fr) * 2006-07-24 2008-10-03 Genfit Sa Derives d'imidazolones substitues, preparation et utilisations
EP1908469A1 (de) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II Rezeptor Antagonisten zur Behandlung von systemischen Krankheiten bei Katzen
US20100029710A1 (en) * 2006-12-21 2010-02-04 Pfizer Products Inc. COMPOUNDS HAVING BOTH ANGIOTENSIN II RECEPTOR ANTAGONISM AND PPARy ACTIVATING ACTIVITIES
WO2008096820A1 (ja) * 2007-02-07 2008-08-14 Kyowa Hakko Kirin Co., Ltd. ビフェニル誘導体
JP4866901B2 (ja) * 2007-02-07 2012-02-01 協和発酵キリン株式会社 ３環系化合物
EP2120581A4 (de) * 2007-02-20 2011-03-16 Melior Pharmaceuticals I Inc Verfahren zur identifikation von aktivatoren der lyn-linase
MX2009010790A (es) * 2007-04-05 2009-10-29 Daiichi Sankyo Co Ltd Derivados de heteroarilo biciclico fusionados.
US11241420B2 (en) 2007-04-11 2022-02-08 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
WO2008128126A1 (en) * 2007-04-11 2008-10-23 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
AU2013202267B2 (en) * 2007-04-11 2015-03-19 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
US20160331729A9 (en) * 2007-04-11 2016-11-17 Omeros Corporation Compositions and methods for prophylaxis and treatment of addictions
EP2180894A4 (de) * 2007-07-23 2012-08-29 Melior Pharmaceuticals I Inc Verfahren zur aktivierung von irs-1 und akt
CN101396562A (zh) * 2007-09-28 2009-04-01 北京华安佛医药研究中心有限公司 含有arb的组合物在制备治疗高同型半胱氨酸血症损伤及其相关疾病的药物中的用途
JP2009227668A (ja) * 2008-02-25 2009-10-08 Santen Pharmaceut Co Ltd 角膜上皮バリア機能亢進剤
US8455204B2 (en) 2008-05-27 2013-06-04 Energesis Pharmaceuticals, Inc. Brown adipocyte progenitors in human skeletal muscle and methods for identifying differentiation agents therefor
US8552184B2 (en) * 2008-07-03 2013-10-08 Melior Pharmaceuticals I, Inc. Compounds and methods for treating disorders related to glucose metabolism
EP3081213B1 (de) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Trizyklische verbindung
BRPI0916476A2 (pt) * 2008-12-01 2016-02-16 Invasc Therapeutics Inc composição, método de tratamento para um distúrbio relacionado ao sistema renina-angiotensina-aldosterona, método para reduzir a resistência à insulina, método para tratar um distúrbio relacionado à síndrome metabólica
ES2433225T3 (es) * 2009-01-30 2013-12-10 Takeda Pharmaceutical Company Limited Compuesto con anillos condensados y uso del mismo
WO2010096264A2 (en) 2009-02-03 2010-08-26 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
WO2010091052A2 (en) 2009-02-03 2010-08-12 Children's Medical Center Corporation Methods for enhancing hematopoietic stem/progenitor cell engraftment
CA2754446A1 (en) 2009-03-05 2010-09-10 Daiichi Sankyo Company, Limited Pyridine derivative
MX2011009384A (es) * 2009-03-11 2011-10-11 Omeros Corp Composiciones y metodos para profilaxis y tratamiento de adicciones.
US20120258170A1 (en) * 2009-05-20 2012-10-11 Nutracryst Therapeutics Private Limited Pharmaceutical co-crystals of quercetin
AU2010251194B2 (en) 2009-05-20 2016-02-25 Boehringer Ingelheim Vetmedica Gmbh Pharmaceutical oral telmisartan solution
WO2011047223A1 (en) * 2009-10-16 2011-04-21 Monsanto Technology Llc Methods of polynucleotide detection
EP2311909A1 (de) * 2009-10-16 2011-04-20 Nanoresins AG Hybrid-Partikel von Polymeren und Nanopartikeln
EP2506863A4 (de) * 2009-12-04 2013-07-17 Technologie Biolactis Inc Verfahren zur regulierung von ppar, mit adipositas zusammenhängenden pfaden und ihrer stoffwechselwirkung
EP2363119A1 (de) * 2010-03-05 2011-09-07 Centre Hospitalier Universitaire d'Angers Neue pharmazeutische Zusammensetzung, die zur Behandlung von Patienten mit neurodegenerativen oder neurovaskulären Erkrankungen geeignet ist
WO2011150300A1 (en) 2010-05-28 2011-12-01 Melior Pharmaceuticals I, Inc. Prevention of pancreatic beta cell degeneration
US20120003296A1 (en) * 2010-07-01 2012-01-05 Shantha Totada R New methods of treating dry eye syndrome
TW201219353A (en) 2010-09-07 2012-05-16 Daiichi Sankyo Co Ltd Manufacturing method of benzoates
US20120156202A1 (en) * 2010-11-05 2012-06-21 Shantha Totada R Age related macular degeneration treatment
WO2012115987A2 (en) * 2011-02-21 2012-08-30 The Trustees Of Columbia University In The City Of New York Methods for Treating and Preventing Cardiac Dysfunction in Septic Shock
WO2012118863A1 (en) * 2011-02-28 2012-09-07 The Schepens Eye Research Institute, Inc. Therapies that target autoimmunity for treating glaucoma and optic neuropathy
KR20140051998A (ko) * 2011-08-03 2014-05-02 교와 핫꼬 기린 가부시키가이샤 디벤조옥세핀 유도체
EP2763703B1 (de) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Steuerung von energiehomöostasen im ganzen körper durch mikro-rna regulierung
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
CN103479627A (zh) * 2013-05-16 2014-01-01 武汉光谷百桥国际生物科技有限公司 一种血管紧张素ii的i型受体拮抗剂在促进毛发生长方面的应用
US10251871B2 (en) * 2015-02-05 2019-04-09 Memorial Sloan Kettering Cancer Center Compositions and methods for treatment of edema
EP3609500B1 (de) 2017-04-10 2024-11-13 Melior Pharmaceuticals I, Inc. Behandlung von adipozyten
EP3996709A1 (de) 2019-07-09 2022-05-18 Boehringer Ingelheim Vetmedica GmbH Telmisartan zur behandlung von bluthochdruck bei hunden
WO2021209993A1 (en) * 2020-04-13 2021-10-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Use of metabolic regulators for the treatment of covid-19
CN114073697B (zh) * 2021-01-19 2023-01-24 复旦大学附属肿瘤医院 Bcat2抑制剂在制备预防和/或治疗bcat2介导的相关代谢疾病药物中的用途
CN120392721A (zh) * 2024-01-30 2025-08-01 哈尔滨三联药业股份有限公司 PPARα/δ双重激动剂在治疗多囊肾疾病中的应用

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US402425A (en) 1889-04-30 Wood-grinder for pulp-making
US5958A (en) * 1848-12-05 Henry ruttan
US283774A (en) 1883-08-28 Cut-off for service-pipes
US189514A (en) 1877-04-10 Improvement in street and park lamps
US6087380A (en) 1949-11-24 2000-07-11 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions
US4156003A (en) 1978-08-24 1979-05-22 Ludwig Merckle K.G., Chem. Pharm. Fabrik Treatment of hypertension with combination of clofibrinic acid or clofibrate with cinnarizine
US4812570A (en) 1986-07-24 1989-03-14 Takeda Chemical Industries, Ltd. Method for producing thiazolidinedione derivatives
DE3928177A1 (de) 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5817075A (en) 1989-08-14 1998-10-06 Photogenesis, Inc. Method for preparation and transplantation of planar implants and surgical instrument therefor
US5053420A (en) 1989-10-13 1991-10-01 Pershadsingh Harrihar A Thiazolidine derivatives for the treatment of hypertension
IL95975A (en) 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
US5250554A (en) 1989-10-24 1993-10-05 Takeda Chemical Industries, Ltd. Benzimidazole derivatives useful as angiotensin II inhibitors
DE69129998T2 (de) 1990-02-15 1998-12-24 Takeda Chemical Industries, Ltd., Osaka Pyrimidindionderivate, deren Herstellung und Verwendung
US5284661A (en) 1990-02-22 1994-02-08 Takeda Chemical Industries, Ltd. Fused thiophene derivatives, their production and use
TW201738B (de) 1990-03-20 1993-03-11 Sanofi Co
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5703110A (en) 1990-04-27 1997-12-30 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US6004989A (en) 1990-04-27 1999-12-21 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
US5298497A (en) 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
DE4023369A1 (de) 1990-07-23 1992-01-30 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
AU636066B2 (en) 1990-10-30 1993-04-08 Takeda Chemical Industries Ltd. Thienoimidazole derivatives, their production and use
US5602127A (en) 1991-02-06 1997-02-11 Karl Thomae Gmbh (Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
US5614519A (en) 1991-02-06 1997-03-25 Karl Thomae Gmbh (1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
US5594003A (en) 1991-02-06 1997-01-14 Dr. Karl Thomae Gmbh Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
TW274551B (de) 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
IL102183A (en) * 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
IL102365A0 (en) 1991-07-03 1993-01-14 Merck & Co Inc Substituted triazolinones,their preparation and pharmaceutical compositions containing them
SK695A3 (en) 1992-07-03 1995-07-11 Smithkline Beecham Plc Heterocyclic compounds method of their production and using
GB9217820D0 (en) * 1992-08-21 1992-10-07 Fujisawa Pharmaceutical Co New use
GB9218830D0 (en) 1992-09-05 1992-10-21 Smithkline Beecham Plc Novel compounds
US5741803A (en) 1992-09-05 1998-04-21 Smithkline Beecham Plc Substituted thiazolidinedionle derivatives
DE69333489T2 (de) 1992-09-14 2005-04-14 Takeda Chemical Industries, Ltd. Heterocyclische Verbindungen und ihre Verwendung als Angiotensin II Antagonisten
US5506245A (en) 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
EP0603712B1 (de) 1992-12-22 2001-08-16 Takeda Chemical Industries, Ltd. Heterocyclische Verbindungen mit Angiotensin-II-antagonistischer Wirkung und ihre Anwendung
TW268952B (de) 1993-02-26 1996-01-21 Takeda Pharm Industry Co Ltd
US5721263A (en) 1993-06-07 1998-02-24 Takeda Chemical Industries, Ltd. Pharmaceutical composition for angiotensin II-mediated diseases
EP0635263A3 (de) 1993-06-28 1995-09-27 American Cyanamid Co Angiotensin (AII)-antagonisten als Inhibitoren des Wachstums von Fettgewebe.
CZ154994A3 (en) 1993-07-02 1995-09-13 Senju Pharma Co Visual hypotensive agent
JPH07138258A (ja) 1993-11-16 1995-05-30 Taiho Yakuhin Kogyo Kk チアゾリジンジオン誘導体又はその塩
DE4408497A1 (de) 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
EP0754042A4 (de) 1994-03-29 2004-06-23 Merck & Co Inc Behandlung von atherosklerose mit imidazolen, die den angiotensin ii-rezeptor blockieren
GB9406573D0 (en) * 1994-03-31 1994-05-25 Merck Sharp & Dohme Medicaments
NO305987B1 (no) 1994-04-11 1999-08-30 Sankyo Co Heterosykliske forbindelser med antidiabetisk aktivitet, deres anvendelse og farmasoeytisk preparat inneholdende disse
US5594015A (en) 1994-06-22 1997-01-14 Regents Of The University Of California Thiazolidine derivatives for the treatment of psoriasis
US5958942A (en) 1994-07-15 1999-09-28 Takeda Chemical Industries, Ltd. Tricyclic nitrogen ring compounds, their production and use
CA2159938A1 (en) 1994-10-07 1996-04-08 Hiroaki Yanagisawa Oxime derivatives, their preparation and their therapeutic use
WO1996012719A1 (en) 1994-10-20 1996-05-02 Nippon Chemiphar Co., Ltd. Quinoline derivative
TW403748B (en) 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5902726A (en) 1994-12-23 1999-05-11 Glaxo Wellcome Inc. Activators of the nuclear orphan receptor peroxisome proliferator-activated receptor gamma
US5868728A (en) 1995-02-28 1999-02-09 Photogenesis, Inc. Medical linear actuator for surgical delivery, manipulation, and extraction
US5827865A (en) 1995-03-09 1998-10-27 Smithkline Beecham P.L.C. Heterocyclic compounds as pharmaceutical
US5925656A (en) 1995-04-10 1999-07-20 Dr. Reddy's Research Foundation Compounds having antidiabetic, hypolipidemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6022897A (en) 1995-04-25 2000-02-08 The Salk Institute For Biological Studies Selective modulators of peroxisome proliferator activated receptor-gamma, and methods for the use thereof
CZ293016B6 (cs) 1995-06-01 2004-01-14 Sankyo Company Limited Benzimidazolové deriváty a farmaceutické prostředky s jejich obsahem
US5939442A (en) 1995-06-07 1999-08-17 The Salk Institute For Biological Studies Modulations of peroxisome proliferator activated receptor-γ, and methods for the use thereof
TW438587B (en) 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5942308A (en) * 1995-07-05 1999-08-24 Nitto Denko Corporation Expandable fixing tape
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
GB9600464D0 (en) 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
JP2725665B2 (ja) 1996-01-29 1998-03-11 日本電気株式会社 プリント配線板製造方法
US5859051A (en) 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
US5847008A (en) 1996-02-02 1998-12-08 Merck & Co., Inc. Method of treating diabetes and related disease states
ATE236137T1 (de) 1996-02-02 2003-04-15 Merck & Co Inc Heterocyclische verbindungen als antidiabetische mittel und für die behandlung von fettleibigkeit
US6090836A (en) 1996-02-02 2000-07-18 Merck & Co., Inc. Benzisoxazole-derived antidiabetic compounds
US6020382A (en) 1996-02-02 2000-02-01 Merck & Co., Inc. Method of treating diabetes and related disease states
NZ330774A (en) 1996-04-05 1999-06-29 Takeda Chemical Industries Ltd Pharmaceutical composition having angiotensin ii antagonistic activity or salt thereof with an insulin-sensitivity increasing compound and postprandial hyperglycemia in diabetes mellitus and antagonistic activity and increased insulin-sensitivity
ZA973848B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5801173A (en) 1996-05-06 1998-09-01 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
ZA973850B (en) 1996-05-06 1997-12-02 Reddy Research Foundation Novel antidiabetic compounds having hypolipidaemic, anti-hypertensive properties, process for their preparation and pharmaceutical compositions containing them.
US5919782A (en) 1996-05-06 1999-07-06 Dr. Reddy's Research Foundation Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
CA2257284C (en) 1996-05-31 2005-10-04 Sankyo Company Limited Remedy for autoimmune diseases
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US5885997A (en) 1996-07-01 1999-03-23 Dr. Reddy's Research Foundation Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
AU744518B2 (en) 1996-07-01 2002-02-28 Dr. Reddy's Laboratories Limited Novel heterocyclic compounds process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases
EP0930882A2 (de) 1996-08-02 1999-07-28 Institut Pasteur De Lille Vorbeugung oder behandlung von typ 2 diabetes oder kardiovaskulärer erkrankung mit ppar modulatoren
US6160000A (en) 1996-12-23 2000-12-12 Merck & Co., Inc. Antidiabetic agents based on aryl and heteroarylacetic acids
US6090839A (en) 1996-12-23 2000-07-18 Merck & Co., Inc. Antidiabetic agents
US6113907A (en) 1997-04-15 2000-09-05 University Of Southern California Pharmaceutical grade St. John's Wort
US5843172A (en) 1997-04-15 1998-12-01 Advanced Cardiovascular Systems, Inc. Porous medicated stent
US6313113B1 (en) 1997-04-15 2001-11-06 Reddy-Cheminor, Inc. Heterocyclic compounds having antidiabetic, hypolipidemic and antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6414008B1 (en) 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
US6011031A (en) 1997-05-30 2000-01-04 Dr. Reddy's Research Foundation Azolidinediones useful for the treatment of diabetes, dyslipidemia and hypertension: process for their preparation and pharmaceutical compositions containing them
SE9702305D0 (sv) 1997-06-17 1997-06-17 Astra Ab New thiazolidinedione, oxazolidinedione and oxadiazolidinedione derivatives
ATE267814T1 (de) 1997-10-08 2004-06-15 Sankyo Co Substituierte kondensierte heterocyclische verbindungen
US5899032A (en) * 1997-11-14 1999-05-04 Buzby; Edward Stair structure
ES2259459T3 (es) 1997-11-19 2006-10-01 Takeda Pharmaceutical Company Limited Nuevos inhibidores de apoptosis.
US6008237A (en) 1997-12-19 1999-12-28 Merck & Co., Inc. Arylthiazolidinedione derivatives
AU759255B2 (en) 1998-01-29 2003-04-10 Amgen, Inc. PPAR-gamma modulators
ZA991922B (en) * 1998-03-11 1999-09-13 Smithkline Beecham Corp Novel compositions of eprosartan.
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
US5945308A (en) * 1998-04-03 1999-08-31 Incyte Pharmaceuticals, Inc. Human oxidized LDL receptor
SE9801990D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl propionic acid derivatives and analogs
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
MA26634A1 (fr) 1998-06-04 2004-12-20 Astra Ab Nouveaux derives de l'acide 3-aryl propionique et analogues
EP1083894A1 (de) * 1998-06-08 2001-03-21 Advanced Medicine, Inc. HMG-CoA REDUKTASE MULTIBINDENDE INHIBITOREN
US6468996B1 (en) 1998-10-21 2002-10-22 Novo Nordisk A/S Substituted hetero-polycyclic compounds as PPARα and PPARγ activators
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
GB9824614D0 (en) 1998-11-11 1999-01-06 Glaxo Group Ltd Chemical compounds
US6479524B1 (en) 1998-12-16 2002-11-12 Boehringer Ingelheim Pharma Kg Substituted aryl and heteroaryl derivatives, their production and their use as medicines
UA73492C2 (en) 1999-01-19 2005-08-15 Aromatic heterocyclic compounds as antiinflammatory agents
US6204288B1 (en) 1999-03-08 2001-03-20 The University Of Mississippi 1,2-dithiolane derivatives
TR200102817T2 (tr) 1999-03-12 2002-05-21 Boehringer Ingelheim Pharmaceuticals, Inc. Antiinflamatuar ajanlar olarak faydalı bileşikler
WO2000055152A1 (en) 1999-03-12 2000-09-21 Boehringer Ingelheim Pharmaceuticals, Inc. Aromatic heterocyclic compounds as anti-inflammatory agents
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
SE9902597D0 (sv) 1999-07-06 1999-07-06 Astra Ab New use
GB9919413D0 (en) 1999-08-18 1999-10-20 Zeneca Ltd Chemical compounds
SE9903028D0 (sv) * 1999-08-27 1999-08-27 Astra Ab New use
US6414002B1 (en) 1999-09-22 2002-07-02 Bristol-Myers Squibb Company Substituted acid derivatives useful as antidiabetic and antiobesity agents and method
TWI302149B (en) 1999-09-22 2008-10-21 Bristol Myers Squibb Co Substituted acid derivatives useful as antiodiabetic and antiobesity agents and method
AU7995300A (en) 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
US6525093B1 (en) 1999-11-08 2003-02-25 Calyx Therapeutics Inc. Compounds to treat diabetes and associated conditions
US6451832B2 (en) 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
US6664287B2 (en) 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
PE20020082A1 (es) * 2000-04-12 2002-02-21 Novartis Ag Composicion farmaceutica que comprende un inhibidor de aldosterona-sintasa y un antagonista del receptor de angiotensina ii (at1)
US20040023840A1 (en) * 2000-04-12 2004-02-05 Marc De Gasparo Combination of organic compounds
AU2001267404A1 (en) 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
US20020013334A1 (en) 2000-06-15 2002-01-31 Robl Jeffrey A. HMG-CoA reductase inhibitors and method
AR033390A1 (es) * 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
US6521747B2 (en) 2000-08-28 2003-02-18 Genaissance Pharmaceuticals, Inc. Haplotypes of the AGTR1 gene
US6689385B2 (en) * 2000-11-03 2004-02-10 Chronorx Llc Formulations for the treatment of insulin resistance and type 2 diabetes mellitus
US20020077348A1 (en) * 2000-11-21 2002-06-20 Dean Herbert M. Dosage unit for cardioprotection
WO2002043807A2 (en) 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EP1356815A4 (de) * 2001-01-29 2007-03-07 Takeda Pharmaceutical Schmerzstillende und entzündungshemmende wirkstoffe
ITMI20010203A1 (it) 2001-02-02 2002-08-02 Solchem Italiana Spa Processo per la preparazione di fibrati
AU2002303156A1 (en) 2001-03-23 2002-10-08 Bethesda Pharmaceuticals, Inc. Design and synthesis of optimized ligands for ppar
US6527747B2 (en) * 2001-05-25 2003-03-04 Becton Dickinson And Company Introducer needle assembly having a tethered needle shield
CN1182122C (zh) * 2001-07-30 2004-12-29 中国科学院上海药物研究所 替米沙坦的合成新路线
JP4744081B2 (ja) 2001-08-31 2011-08-10 ラトガーズ， ザ ステイト ユニバーシティ オブ ニュー ジャージー 植物抽出物を用いて障害を処置するための方法
US7232828B2 (en) 2002-08-10 2007-06-19 Bethesda Pharmaceuticals, Inc. PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
DE10301371A1 (de) 2003-01-16 2004-08-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
EP1818056A1 (de) 2003-01-16 2007-08-15 Boehringer Ingelheim International Gmbh Pharmazeutische Kombination zur Prophylaxe oder Therapie von kardiovaskulären, kardiopulmonalen, pulmonalen oder renalen Krankheiten
EP1648515B1 (de) 2003-07-16 2012-11-21 Boehringer Ingelheim International GmbH Chlorthalidon-kombinationen
US20060159747A1 (en) * 2004-12-17 2006-07-20 Boehringer Ingelheim International Gmbh Telmisartan and hydrochlorothiazide combination therapy
AU2005315855A1 (en) 2004-12-17 2006-06-22 Boehringer Ingelheim International Gmbh Combination therapy comprising telmisartan and hydrochlorothiazide

Also Published As

Publication number Publication date
EP1536785A4 (de) 2005-11-16
KR20080005460A (ko) 2008-01-11
KR20080006648A (ko) 2008-01-16
DK1536785T3 (da) 2007-09-24
KR100869450B1 (ko) 2008-11-19
DE60314155D1 (de) 2007-07-12
WO2004014308A3 (en) 2004-08-12
JP2006515566A (ja) 2006-06-01
EP1842542A1 (de) 2007-10-10
ATE363277T1 (de) 2007-06-15
DE60334942D1 (de) 2010-12-23
US20040127443A1 (en) 2004-07-01
PL375189A1 (en) 2005-11-28
CN1688305A (zh) 2005-10-26
JP2009235103A (ja) 2009-10-15
US7232828B2 (en) 2007-06-19
CN101683530A (zh) 2010-03-31
AU2003259081A1 (en) 2004-02-25
HK1078021A1 (en) 2006-03-03
US20070185070A1 (en) 2007-08-09
EP1878427A1 (de) 2008-01-16
CN101683529A (zh) 2010-03-31
EP1886683B1 (de) 2010-11-10
JP4669285B2 (ja) 2011-04-13
CA2494909A1 (en) 2004-02-19
US20070054949A1 (en) 2007-03-08
EP1842542A3 (de) 2008-07-16
AU2003259081B2 (en) 2010-03-11
HK1110786A1 (en) 2008-07-25
MXPA05001543A (es) 2005-08-19
EP1886683A1 (de) 2008-02-13
US20110046188A1 (en) 2011-02-24
CN100548293C (zh) 2009-10-14
JP2009235102A (ja) 2009-10-15
US7867991B2 (en) 2011-01-11
EP1536785A2 (de) 2005-06-08
DE60314155T2 (de) 2008-01-24
ATE536183T1 (de) 2011-12-15
ES2385936T3 (es) 2012-08-03
US20080009536A1 (en) 2008-01-10
DK1886683T3 (da) 2011-02-21
EP1839660A1 (de) 2007-10-03
CN101683528A (zh) 2010-03-31
US7812046B2 (en) 2010-10-12
WO2004014308A2 (en) 2004-02-19
EP1859799B1 (de) 2011-12-07
KR20080065004A (ko) 2008-07-10
EP1536785B1 (de) 2007-05-30
US20120094913A1 (en) 2012-04-19
KR100869449B1 (ko) 2008-11-19
ES2288631T3 (es) 2008-01-16
CA2494909C (en) 2012-01-10
US20080242712A1 (en) 2008-10-02
CN101683335A (zh) 2010-03-31
CN101683531A (zh) 2010-03-31
KR20050055701A (ko) 2005-06-13
US20070203213A1 (en) 2007-08-30
KR100830861B1 (ko) 2008-05-21
EP1859799A1 (de) 2007-11-28
AU2009201471A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
DE60334942D1 (de) Neue PPAR-Liganden, die keine Flüssigkeitsretentionen, Ödeme oder kongestive Herzinsuffizienzen verursachen
JP2005518433A5 (de)
WO2005047244A3 (en) Inhibition of fgfr3 and treatment of multiple myeloma
DE69841291D1 (de) Verwendung von Botulinumtoxin zur Behandlung der renitenten Blasenentleerungsstörung
HRP20141048T1 (hr) Spojevi, pripravci i metode
IS8255A (is) P38 kínasatálmar staðsettir á 5 hluta heteróhring
NO20051262L (no) Anvendelse av CGRP-antagonistforbindelser for behandling av psoriasis
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
UY27689A1 (es) Nuevos derivados de tiazol como antagonistas del receptor npy
DE69431623D1 (de) Hemmung, bekämpfung und regression der angiogenese mit hyaluronsäure oder hyaluronsäure und nsaid
EA200501058A1 (ru) Фармацевтическая комбинация из телмисартана и аторвастатина для профилактики или терапевтического лечения сердечно-сосудистых, сердечно-легочных, легочных или почечных заболеваний
WO2005075450A3 (en) Spiro-benzodioxoles and their use as cb1 antagonists
WO2000048446A3 (en) Use of antagonists of pg-e for the treatment of neuropathic pain
ZA200705889B (en) New 3-phenylpropionic acid derivatives and their use as PPAR-GAMMA receptor ligands
WO2003051290A3 (en) Treating b-cell mediated diseases by modulating dr6 activity
DE60018186D1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
IS4847A (is) Aðferð til meðferðar gegn hjartabilun þar sem notuð eru mótlyf gegn endóþelíni
NO20016000L (no) Aminotetralin-derivat for terapien av kardiovaskul¶re sykdommer
AR131602A1 (es) Uso del compuesto 1 en el tratamiento o prevención de la fibrosis renal y otras enfermedades
RU2002114397A (ru) Способ лечения мастита у коров
WO2006124544A3 (en) Use of tyrosine kinase inhibitors in the treatment of metabolic disorders
CN100473380C (zh) 一种治疗脚癣的药物
KR200193398Y1 (ko) 무좀치료용 스프레이
RU2019126012A (ru) Способ лечения венозной тромбоэмболии
RU2002115650A (ru) Способ борьбы с болезнями пчел

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1886683

Country of ref document: EP